Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

962 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators. Bentley-Lewis R, et al. Among authors: maggioni ap. Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12. Am Heart J. 2015. PMID: 25965710 Free article. Clinical Trial.
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM; VALIANT Investigators. Velazquez EJ, et al. Among authors: maggioni ap. Eur J Heart Fail. 2003 Aug;5(4):537-44. doi: 10.1016/s1388-9842(03)00112-0. Eur J Heart Fail. 2003. PMID: 12921816 Free article.
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Pfeffer MA, et al. Among authors: maggioni ap. N Engl J Med. 2003 Nov 13;349(20):1893-906. doi: 10.1056/NEJMoa032292. Epub 2003 Nov 10. N Engl J Med. 2003. PMID: 14610160 Free article. Clinical Trial.
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.
Velazquez EJ, Francis GS, Armstrong PW, Aylward PE, Diaz R, O'Connor CM, White HD, Henis M, Rittenhouse LM, Kilaru R, van Gilst W, Ertl G, Maggioni AP, Spac J, Weaver WD, Rouleau JL, McMurray JJ, Pfeffer MA, Califf RM; VALIANT registry. Velazquez EJ, et al. Among authors: maggioni ap. Eur Heart J. 2004 Nov;25(21):1911-9. doi: 10.1016/j.ehj.2004.08.006. Eur Heart J. 2004. PMID: 15522470
Left ventricular assessment in myocardial infarction: the VALIANT registry.
Hernandez AF, Velazquez EJ, Solomon SD, Kilaru R, Diaz R, O'Connor CM, Ertl G, Maggioni AP, Rouleau JL, van Gilst W, Pfeffer MA, Califf RM; VALIANT Registry. Hernandez AF, et al. Among authors: maggioni ap. Arch Intern Med. 2005 Oct 10;165(18):2162-9. doi: 10.1001/archinte.165.18.2162. Arch Intern Med. 2005. PMID: 16217008
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger JD, Califf RM. Køber L, et al. Among authors: maggioni ap. Eur J Heart Fail. 2006 Oct;8(6):591-8. doi: 10.1016/j.ejheart.2005.11.007. Epub 2006 Feb 28. Eur J Heart Fail. 2006. PMID: 16507350 Free article. Clinical Trial.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S. Ducharme A, et al. Among authors: maggioni ap. Am Heart J. 2006 May;151(5):985-91. doi: 10.1016/j.ahj.2005.06.036. Am Heart J. 2006. PMID: 16644318
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators. Ducharme A, et al. Among authors: maggioni ap. Am Heart J. 2006 Jul;152(1):86-92. Am Heart J. 2006. PMID: 16838426
962 results